메뉴 건너뛰기




Volumn 32, Issue 12, 1998, Pages 1334-1343

Topotecan: A new topoisomerase I inhibiting antineoplastic agent

Author keywords

Breast; Cancer; Leukemia; Lung; Ovarian; Topotecan; Uterus

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; TOPOTECAN;

EID: 0032425604     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18049     Document Type: Review
Times cited : (26)

References (8)
  • 2
    • 0029552468 scopus 로고
    • Molecular, cellular, and clinical aspects of the pharmacology of 20 (S)-camptothecin and its derivatives
    • Rivory LP, Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20 (S)-camptothecin and its derivatives. Pharmacol Ther 1995;68:269-96.
    • (1995) Pharmacol Ther , vol.68 , pp. 269-296
    • Rivory, L.P.1    Robert, J.2
  • 4
    • 0027323646 scopus 로고
    • Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant GCSF
    • Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant GCSF. J Natl Cancer Inst 1993; 85:1499-1507.
    • (1993) J Natl Cancer Inst , vol.85 , pp. 1499-1507
    • Saltz, L.1    Sirott, M.2    Young, C.3    Tong, W.4    Niedzwiecki, D.5    Tzy-Jyun, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.